The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO).
Gianluca Masi
Honoraria - Roche
Fotios Loupakis
No relevant relationships to disclose
Lisa Salvatore
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Lorenzo Fornaro
No relevant relationships to disclose
Marta Schirripa
No relevant relationships to disclose
Cristina Granetto
No relevant relationships to disclose
Emanuela Miraglio
No relevant relationships to disclose
Francesco Di Costanzo
No relevant relationships to disclose
Lorenzo Antonuzzo
No relevant relationships to disclose
Lorenzo Marcucci
No relevant relationships to disclose
Cecilia Barbara
No relevant relationships to disclose
Corrado Boni
No relevant relationships to disclose
Maria Banzi
No relevant relationships to disclose
Silvana Chiara
No relevant relationships to disclose
Daniela Garbarino
No relevant relationships to disclose
Chiara Valsuani
No relevant relationships to disclose
Andrea Bonetti
No relevant relationships to disclose
Luca Boni
No relevant relationships to disclose
Alfredo Falcone
Consultant or Advisory Role - Amgen; Bayer; Merck; Roche
Honoraria - Amgen; Bayer; Merck; Roche
Research Funding - Amgen; Bayer; Merck; Roche